Why Is NEKTAR THERAPEUTICS (NKTR) Stock Down Today?

Nektar Therapeutics (NKTR) fell 22.39% to $46.99 on Thursday, marking one of the stock’s worst days in over three years. The sharp decline followed the company’s announcement of new mid-stage trial data for its hair loss candidate, rezpegaldesleukin. While William Blair highlighted a potential durability edge in the data, the broader market reaction was negative, with Jefferies calling the selloff "unwarranted." The stock’s performance was also influenced by recent insider sales and a broader trend of declining investor confidence.

What Happened

Nektar disclosed data from two trials of rezpegaldesleukin for alopecia and eczema, but the market interpreted the results as underwhelming. The stock opened lower and continued to fall throughout the session, closing at $46.99. Analysts and investors reacted with mixed sentiment. William Blair maintained a positive outlook, while Jefferies questioned the magnitude of the selloff. The Fly reported that the stock had dropped -21.6% at one point, and Barron’s noted the decline despite what it described as "promising" data. The company also presented the findings at the European Academy of Dermatology and Venereology, but the stock remained under pressure.

What The Data Shows

Nektar’s stock has fallen 25.6% over the past eight sessions, from $66.41 to $49.41. The current price of $46.99 is within the 52-week range of $33.40 to $109.00 and has now printed 20 fresh 52-week lows on October 1. The stock’s fundamentals remain weak, with a market cap of $2.0B, unprofitable earnings (TTM EPS -6.47), and a net margin of -287.8%. Recent insider transactions include two sales by executives totaling $43K, with the most recent filing on August 20. The stock’s beta of 1.15 indicates it is more volatile than the broader market.

What To Watch

Nektar does not have an upcoming earnings date listed. Investors should monitor the breadth of analyst coverage and any follow-up commentary from William Blair or Jefferies. The stock’s continued volatility and insider activity may influence near-term sentiment.